IPHA vs. AGEN, ZURA, CHRS, ABOS, CMPX, GLUE, INMB, IVVD, GNFT, and ELEV
Should you be buying Innate Pharma stock or one of its competitors? The main competitors of Innate Pharma include Agenus (AGEN), Zura Bio (ZURA), Coherus BioSciences (CHRS), Acumen Pharmaceuticals (ABOS), Compass Therapeutics (CMPX), Monte Rosa Therapeutics (GLUE), INmune Bio (INMB), Invivyd (IVVD), Genfit (GNFT), and Elevation Oncology (ELEV). These companies are all part of the "biological products, except diagnostic" industry.
Innate Pharma (NASDAQ:IPHA) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.
Agenus received 426 more outperform votes than Innate Pharma when rated by MarketBeat users. Likewise, 70.14% of users gave Agenus an outperform vote while only 54.93% of users gave Innate Pharma an outperform vote.
0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 4.6% of Agenus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Agenus had 4 more articles in the media than Innate Pharma. MarketBeat recorded 11 mentions for Agenus and 7 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 0.60 beat Agenus' score of 0.51 indicating that Innate Pharma is being referred to more favorably in the media.
Innate Pharma has higher earnings, but lower revenue than Agenus.
Innate Pharma presently has a consensus target price of $9.75, indicating a potential upside of 235.22%. Agenus has a consensus target price of $70.00, indicating a potential upside of 359.02%. Given Agenus' higher possible upside, analysts plainly believe Agenus is more favorable than Innate Pharma.
Innate Pharma has a net margin of 0.00% compared to Agenus' net margin of -154.88%.
Innate Pharma has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Agenus has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.
Summary
Agenus beats Innate Pharma on 8 of the 14 factors compared between the two stocks.
Get Innate Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IPHA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Innate Pharma Competitors List
Related Companies and Tools
